🎉 OBI-902 receives a Second FDA Orphan Drug Designation, this time for gastric cancer including gastroesophageal junction adenocarcinoma.
We remain committed to advancing OBI-902 in areas of high unmet medical need. 🔬
#ADC #OBI902 #TROP2 #GlycOBI #ODD #GC #GEJC

www.obipharma.com/news/obi-902...

OBI’s TROP2 ADC OBI-902 has been granted Orphan Drug Designation by the U.S. FDA for the treatment of cholangiocarcinoma, a rare and aggressive cancer with limited treatment options.
#OBIPharma #OBI902 #ADC #OrphanDrugDesignation #Cholangiocarcinoma

www.accessnewswire.com/newsroom/en/...

🚀 OBI Pharma has enrolled the first patient in our Phase 1/2 clinical trial of OBI-902, our first TROP2-targeted ADC built with our proprietary GlycOBI® technology.
🔗 Learn more: www.globenewswire.com/news-release...
#OBIPharma #ADC #ClinicalTrials
#GlycOBI #OBI902 #Phase1 #firstpatientin

At the 2025 Taiwan Society for Immunotherapy of Cancer (TSITC) Summer Meeting,
OBI Pharma CEO Dr. Heidi Wang presented on:
📌Insights from US FDA rejection letters (CRLs)
📌Principles and key considerations in drug development
#OBIPharma #ADCs #TSITC2025 #DrugDevelopment #PrecisionMedicine #OBI902